For patients with type 2 diabetes mellitus (T2DM) and tobacco use disorder (TUD), new use of semaglutide is associated with lower risk of TUD-related health care measures compared with other antidiabetes medications, according to a study published online July 30 in the Annals of Internal Medicine.
Semaglutide seems beneficial for comorbid type 2 diabetes mellitus, tobacco use disorder retrieved 30 July 2024 from https://medicalxpress.com/news/2024-07-semaglutide-beneficial-comorbid-diabetes-mellitus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.15 hours ago Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study shows sedative exams like endoscopy may require prolonged fasting for semaglutide usersA study published in the Journal of Clinical Anesthesia investigated the relationship between semaglutide use and residual gastric content in patients undergoing upper gastrointestinal endoscopy (EGD).
Read more »
Tirzepatide outperforms semaglutide in weight loss for overweight and obese adultsTirzepatide leads to significantly greater weight loss than semaglutide in overweight or obese adults, with no significant difference in gastrointestinal adverse effects.
Read more »
Semaglutide found to cut major adverse cardiovascular events in people with overweight, obesitySemaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published online June 22 in Diabetes Care.
Read more »
Semaglutide linked to increased risk of severe eye condition NAION in new studyResearch shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.
Read more »
Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetesA study from the University of Nottingham shows that combining Semaglutide with a very-low calorie diet significantly improves weight loss and glycemic control in type 2 diabetes patients.
Read more »
Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetesResearchers found that adherence and persistence in T2D patients using oral semaglutide is similar to DPP-4i, but semaglutide users required fewer concurrent medications, indicating higher long-term efficacy.
Read more »